Two Sigma Securities LLC Makes New Investment in Novartis AG $NVS

Two Sigma Securities LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) in the second quarter, HoldingsChannel reports. The institutional investor purchased 3,246 shares of the company’s stock, valued at approximately $509,000.

Several other hedge funds also recently modified their holdings of the company. SOA Wealth Advisors LLC. grew its holdings in Novartis by 4,316.2% during the second quarter. SOA Wealth Advisors LLC. now owns 14,750 shares of the company’s stock worth $2,312,000 after acquiring an additional 14,416 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Novartis by 40.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock valued at $30,715,000 after acquiring an additional 56,424 shares during the last quarter. Presilium Private Wealth LLC acquired a new stake in Novartis in the 1st quarter valued at about $703,000. Brighton Jones LLC boosted its position in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares in the last quarter. Finally, Mission Wealth Management LP boosted its position in shares of Novartis by 85.7% during the 2nd quarter. Mission Wealth Management LP now owns 19,690 shares of the company’s stock valued at $3,086,000 after purchasing an additional 9,086 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Price Performance

Shares of NVS opened at $162.42 on Thursday. The company has a market capitalization of $309.93 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 3.14 and a beta of 0.45. Novartis AG has a fifty-two week low of $121.57 and a fifty-two week high of $170.46. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The business’s 50-day moving average is $155.48 and its 200-day moving average is $153.74.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The company had revenue of $14.95 billion for the quarter. Equities research analysts expect that Novartis AG will post 8.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of research reports. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Citigroup restated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Novartis presently has an average rating of “Hold” and a consensus price target of $141.20.

Key Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Remibrutinib cleared two Phase III multiple sclerosis trials. The oral drug significantly reduced annualized relapse rates versus teriflunomide (Aubagio) in relapsing multiple sclerosis and also showed favorable results on MRI lesion measures. Novartis said a combined analysis indicated a clinically meaningful delay in disability progression, strengthening the drug’s potential commercial profile and supporting plans for global regulatory submissions. Novartis oral multiple sclerosis drug meets main goal in late stage studies
• Positive Sentiment: The positive MS data are viewed as an important growth catalyst. Analysts and investors see remibrutinib as a potential future blockbuster in a large market, particularly because it outperformed an established treatment and reportedly showed no liver-safety signal. The results prompted a sharp prior-session rally and could improve confidence in Novartis’ longer-term product pipeline. Novartis’ Remibrutinib Delivers Positive Results in Late-Stage MS Studies
• Positive Sentiment: Novartis signed a potential $3.2 billion Hybrozyme agreement with Alteogen. The deal could expand access to Alteogen’s drug-delivery technology and support development or commercialization of future medicines, though the financial commitment and deal milestones may limit the near-term earnings benefit. Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
• Neutral Sentiment: Novartis plans to relocate laboratory activities and shut down some Basel production operations, potentially affecting about 130 jobs. The restructuring may improve efficiency over time but creates near-term execution and employee-transition costs. Novartis could cut about 130 jobs in Basel site relocation
• Negative Sentiment: Novartis paused eight autoimmune and neurological cell-therapy trials after three patient deaths. The pauses raise safety, regulatory and development risks for the experimental rap-cel program and prompted a customer-related setback for Oxford BioMedica, though the issue is separate from remibrutinib. Novartis pauses autoimmune cell therapy studies after deaths

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.